From Wikipedia, the free encyclopedia
Chemical compound
Imeglimin
Trade names Twymeeg
ATC code
Legal status
(2S )-N 6 ,N 6 ,2-Trimethyl-1,2-dihydro-1,3,5-triazine-4,6-diamine
CAS Number
PubChem
CID
ChemSpider
UNII
CompTox Dashboard (
EPA )
Formula C 6 H 13 N 5
Molar mass 155.205 g·mol−1 3D model (
JSmol )
C[C@H]1NC(=NC(=N1)N)N(C)C
InChI=1S/C6H13N5/c1-4-8-5(7)10-6(9-4)11(2)3/h4H,1-3H3,(H3,7,8,9,10)/t4-/m1/s1
Key:GFICWFZTBXUVIG-SCSAIBSYSA-N
Imeglimin (EMD- 387008,PXL- 008,RVT-1501, brand name Twymeeg ) is an oral
anti-diabetic medication.
[1]
[2] It was approved for use in Japan in June 2021.
[3]
It is an
oxidative phosphorylation blocker that acts to inhibit hepatic
gluconeogenesis , increase muscle
glucose uptake, and restore normal insulin secretion. It is the
first approved drug of this class of anti-diabetic medication.
References
^ Vuylsteke V, Chastain LM, Maggu GA, Brown C (September 2015).
"Imeglimin: A Potential New Multi-Target Drug for Type 2 Diabetes" . Drugs in R&D . 15 (3): 227–32.
doi :
10.1007/s40268-015-0099-3 .
PMC
4561051 .
PMID
26254210 .
^ Dubourg J, Fouqueray P, Thang C, Grouin JM, Ueki K (April 2021).
"Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients With Type 2 Diabetes (TIMES 1): A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 Trial" . Diabetes Care . 44 (4): 952–959.
doi :
10.2337/dc20-0763 .
PMID
33574125 .
^ Poxel SA (June 23, 2021).
"Poxel and Sumitomo Dainippon Pharma Announce the Approval of TWYMEEG® (Imeglimin hydrochloride) for the Treatment of Type 2 Diabetes in Japan" (Press release).
fast-acting short-acting long-acting ultra-long-acting
inhalable